Skip to main content
Premium Trial:

Request an Annual Quote

Caliper's Shares Gain Back Some Ground After Sharp Drop

This article has been updated to reflect Friday's rise in Caliper's stock price.
 
NEW YORK (GenomeWeb News) – Shares of Caliper Life Sciences rose around 16 percent on Friday, following a drop of 21 percent on Thursday.
 
Caliper's shares had fallen sharply a day after the firm reported a 4 percent decline in second-quarter revenues and an analyst said his revenue outlook for the year was below the firm’s guidance.
 
On Wednesday, Caliper reported that its second-quarter revenues declined to $34 million from $35.3 million, a drop that was expected and was due primarily to a decrease in revenues and contract delays related to agreements with Pfizer and the Environmental Protection Agency. Caliper President and CEO Kevin Hrusovsky said during the firm’s conference call that day that the firm is “confident that this situation will correct itself in the second half.”
 
The firm said that it expects full-year revenues of between $142 million and $148 million, which would require an acceleration of sales in the second half of the year.
 
However, Leerink Swann analyst Isaac Ro said in a research note yesterday that his firm is taking a “conservative outlook” for Caliper’s second half and his fiscal-year 2008 revenue outlook for Caliper is below the guidance range.
 
One other issue that may have hit the firm’s stock is Caliper’s cash on hand and burn rate. The firm finished the quarter with $10.6 million in cash, cash equivalents, and marketable securities. An analyst on the conference call said that he had calculated that Caliper had burned through roughly $7.6 million in Q2, a figure that was not disputed by Caliper officials.
 
“I do think that Q2 was somewhat extraordinary relative to the cash usage,” Hrusovsky said in response to the question regarding the company’s cash resources. “As we pointed out, we’ve been paying like a million bucks a quarter for lease payments for idle facilities, and there are some other extraordinary things in there. Moving forward, we’re actually feeling quite confident regarding our ability to manage our cash,” he said.
 
“We really don’t want to do a raise,” said Hrusovsky. “That’s our objective. We still feel confident that based on what we see in the future, we’re going to be able to avoid that. There’s no guarantee of that, but that’s clearly our intention and we’ve held to that for at least the last four or five quarters.”
 
Caliper's shares gained back some of the ground it lost on Thursday, and in late Friday afternoon trade on the Nasdaq was up 15.6 percent at $3.48.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.